Nyxoah S.A.

NasdaqGM NYXH

Nyxoah S.A. Return on Assets (ROA) for the year ending December 31, 2023: -34.80%

Nyxoah S.A. Return on Assets (ROA) is -34.80% for the year ending December 31, 2023, a -62.82% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Nyxoah S.A. Return on Assets (ROA) for the year ending December 31, 2022 was -21.38%, a -32.22% change year over year.
Nyxoah S.A. Return on Assets (ROA) for the year ending December 31, 2021 was -16.17%, a -50.62% change year over year.
Nyxoah S.A. Return on Assets (ROA) for the year ending December 31, 2020 was -10.73%, a 77.52% change year over year.
Nyxoah S.A. Return on Assets (ROA) for the year ending December 31, 2019 was -47.75%, a 5.45% change year over year.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

NasdaqGM: NYXH

Nyxoah S.A.

CEO	Mr. Olivier Taelman
IPO Date	April 28, 2021
Location	Belgium
Headquarters	Rue Edouard Belin 12
Employees	146
Sector	Health Care
Industries Pharmaceuticals Telehealth

Description

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Key trends

Past 5 years